List of Excipients in Branded Drug READI-CAT 2

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
E-Z-EM Canada Inc	READI-CAT 2	barium sulfate	32909-724	ANHYDROUS CITRIC ACID
E-Z-EM Canada Inc	READI-CAT 2	barium sulfate	32909-724	DIMETHICONE 1000
E-Z-EM Canada Inc	READI-CAT 2	barium sulfate	32909-724	DIMETHICONE 350
E-Z-EM Canada Inc	READI-CAT 2	barium sulfate	32909-724	POTASSIUM SORBATE

READI-CAT 2 Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: September 5, 2026

READI-CAT 2 is a barium sulfate oral suspension marketed by Bracco Diagnostics for gastrointestinal and abdominal CT imaging. Its commercial value depends less on active-ingredient exclusivity than on suspension stability, dose uniformity, palatability, packaging, radiopacity, manufacturing consistency, and hospital workflow integration. The product is exposed to generic and private-label competition because barium sulfate is an established diagnostic agent with limited formulation complexity and no biosimilar barrier.

What is READI-CAT 2 and how does its formulation work?

READI-CAT 2 contains barium sulfate at 2% weight/volume. The product is administered orally as a positive-contrast agent to opacify the gastrointestinal tract during radiographic and CT examinations. The FDA label identifies barium sulfate as the active ingredient and lists excipients that support suspension performance, taste, preservation, and pH control. [1]

The reported inactive ingredients include:

Excipient or component	Primary formulation function
Carboxymethylcellulose sodium	Suspending and viscosity-control agent
Xanthan gum	Suspension stabilization and rheology control
Sorbitol	Sweetener, humectant and mouthfeel modifier
Sodium saccharin	High-intensity sweetener
Citric acid	Acidulant and pH adjustment
Sodium citrate	Buffering and pH control
Potassium sorbate	Preservative
Flavor	Palatability improvement
Purified water	Vehicle

The formulation must keep insoluble barium sulfate particles evenly distributed during storage and use. A patient or imaging technician must be able to obtain a reproducible dose after ordinary shaking or handling. Excessive viscosity can impair pouring and patient acceptance; insufficient viscosity can cause sedimentation and dose variability.

The formulation also has to balance four competing properties:

1. Physical stability during shelf life.
2. Rapid and adequate redispersion.
3. Acceptable oral taste and texture.
4. Consistent radiographic contrast at the administered volume.

The excipient system is therefore commercially relevant even where it is not protected by a currently enforceable patent.

What excipients are most important in READI-CAT 2?

Suspending agents

Carboxymethylcellulose sodium and xanthan gum are central to suspension performance. Their combined use can provide both low-shear viscosity and structural recovery after pouring. The target is a suspension that resists sedimentation while remaining pourable and capable of redispersion.

Potential development variables include:

• Polymer concentration.
• Degree of substitution and viscosity grade of carboxymethylcellulose.
• Xanthan gum grade and hydration behavior.
• Order of addition.
• High-shear mixing conditions.
• Particle-size distribution of barium sulfate.
• Bulk density and wetting characteristics.

A competitor that changes polymer grade or concentration may obtain a different sedimentation profile without changing the active ingredient. Such a change can create a product differentiation opportunity, but it may also require comparative stability, viscosity, redispersion, and dose-uniformity data.

Sweeteners and flavoring

Sorbitol, sodium saccharin, and flavoring address the primary adherence problem for oral contrast: the patient must consume a relatively large liquid volume despite the dense, chalky character of barium sulfate.

Commercial opportunities include:

• Improved flavor systems.
• Lower residual aftertaste.
• Reduced perceived thickness.
• Pediatric-oriented products.
• Sugar-reduced or sugar-free alternatives.
• Flavor variants for different institutional preferences.
• Masking of polymer or preservative taste.

Flavor changes may be commercially useful but can complicate regulatory comparability, stability, and packaging assessments. A flavor system that performs well in development may interact with preservatives, polymers, or the container closure system.

Buffering and preservation

Citric acid and sodium citrate help control pH. Potassium sorbate provides antimicrobial preservation in the aqueous suspension. The pH must support preservative performance without creating unacceptable taste, instability, or container interaction.

Preservative-reduced or preservative-free formats could have commercial appeal, particularly for products designed for immediate preparation or single-use administration. The tradeoff is greater dependence on manufacturing controls, packaging integrity, in-use stability, and microbial limits.

What formulations are protected by READI-CAT 2 patents?

Publicly available FDA product information identifies the READI-CAT 2 formulation and its ingredients, but the product's commercial position does not appear to depend on a broad, active-ingredient patent estate comparable to a conventional small-molecule drug. Barium sulfate has been used as a radiographic contrast agent for decades, and the principal competitive barriers are formulation know-how, quality systems, regulatory documentation, supply reliability, and customer relationships.

The likely protectable subject matter includes:

• Specific polymer ratios.
• Particle-size distributions.
• Redispersion performance.
• Flavor and sweetener combinations.
• Preservative systems.
• Manufacturing sequence and shear conditions.
• Container designs that reduce settling or leakage.
• Ready-to-use packaging.
• Unit-dose or premeasured administration systems.

These features may be protected through patents, trade secrets, confidential manufacturing procedures, trademarks, or regulatory know-how. Public product labeling alone does not establish that a specific excipient combination remains patent-protected.

A formulation patent would need claims that distinguish the product from earlier barium sulfate suspensions. Broad claims to an aqueous barium sulfate suspension with common excipients would face substantial prior-art risk. Narrow claims directed to a defined rheological profile, particle-size range, redispersion time, or packaging configuration would have a better chance of surviving validity challenges but would provide narrower enforcement coverage.

What is the Orange Book status of READI-CAT 2?

READI-CAT 2 is an FDA-approved prescription diagnostic product. FDA approval establishes the product's safety, efficacy, quality, labeling, and manufacturing basis under its approved application. [1,2]

The Orange Book framework is principally relevant to approved prescription drug products and their listed patents, therapeutic-equivalence evaluations, and generic applications. [2] For a barium sulfate suspension, the commercial relevance of Orange Book protection depends on whether the reference product has listed patents or exclusivity that constrain an ANDA applicant.

The practical assessment is:

Issue	READI-CAT 2 commercial impact
Active-ingredient exclusivity	Limited; barium sulfate is longstanding
Biosimilar exclusivity	Not applicable
Formulation patent risk	Potentially relevant but likely narrow
Method-of-use patents	Limited practical value for a diagnostic contrast agent
ANDA competition	Potentially meaningful
Paragraph IV risk	Relevant only if an enforceable listed patent exists
Trade-secret risk	More important for manufacturing know-how
Brand differentiation	Taste, suspension quality, availability and workflow

A definitive patent conclusion requires a current Orange Book patent listing and associated FDA application records. The publicly visible product profile does not indicate that READI-CAT 2 relies on a major, late-expiring patent barrier.

When does READI-CAT 2 lose exclusivity?

READI-CAT 2's core market exclusivity is substantially different from that of a newly approved therapeutic drug. Barium sulfate is an established active ingredient, and its clinical use is not dependent on a novel molecular entity.

The relevant loss-of-exclusivity questions are:

1. Whether FDA grants or maintains product-specific exclusivity.
2. Whether a listed formulation or method patent remains enforceable.
3. Whether an ANDA applicant can demonstrate pharmaceutical equivalence and bioequivalence or satisfy the applicable requirements for a complex suspension.
4. Whether state and institutional purchasing contracts favor the incumbent.
5. Whether the entrant can meet manufacturing and supply requirements.

For a product of this type, market entry may occur without waiting for a conventional composition-of-matter patent expiration if no enforceable listed patent blocks approval. Generic entry can still be delayed by formulation complexity, reference-product sourcing, FDA review questions, manufacturing scale-up, or inability to match physical performance.

Are there Paragraph IV challenges to READI-CAT 2?

Paragraph IV litigation arises when an ANDA applicant certifies that a listed patent is invalid, unenforceable, or not infringed. [3] A Paragraph IV challenge would be commercially material only if READI-CAT 2 had an Orange Book-listed patent with remaining enforceable life.

There is no widely recognized Paragraph IV litigation profile associated with READI-CAT 2 comparable to heavily litigated branded therapeutics. That reduces litigation-driven delay risk but also indicates that the main competitive threat may come from routine generic approval, private-label supply, or institutional contracting rather than patent litigation.

Potential litigation theories would include:

• Infringement of a formulation patent.
• Infringement of a manufacturing-process patent.
• Invalidity based on anticipation or obviousness.
• Noninfringement based on different excipient ratios or particle sizes.
• Regulatory exclusivity disputes.
• Trademark or trade-dress disputes involving product presentation.

What generic entry risks exist for READI-CAT 2?

Generic and private-label entrants face a lower molecular-risk profile than entrants targeting novel therapeutic drugs, but they still face technical and commercial hurdles.

Technical barriers

A competing suspension must control:

• Sedimentation rate.
• Redispersion behavior.
• Viscosity across temperature ranges.
• Barium sulfate concentration.
• Particle-size distribution.
• Microbial quality.
• Preservative effectiveness.
• Container compatibility.
• Dose uniformity after storage and shaking.

The most important development risk is that two products with the same barium sulfate concentration may perform differently in use. A product that settles rapidly, forms hard sediment, pours inconsistently, or has poor taste may fail institutional evaluation even if it satisfies basic identity and strength requirements.

Commercial barriers

Hospitals and imaging centers typically value:

• Reliable supply.
• Consistent bottle fill.
• Easy opening and pouring.
• Low preparation time.
• Patient acceptance.
• Compatibility with existing imaging protocols.
• Competitive acquisition cost.
• Vendor service and recall performance.

A lower-cost entrant may therefore need to offer more than an equivalent concentration. Unit-dose packaging, improved labeling, simplified preparation, or better supply continuity can support conversion.

What commercial opportunities exist in READI-CAT 2 excipients?

Improved patient acceptability

The strongest formulation opportunity is palatability. A better flavor and mouthfeel profile can reduce incomplete dosing and improve workflow in outpatient imaging centers.

Potential product concepts include:

• Citrus, berry, vanilla, or neutral flavor systems.
• Lower-viscosity suspensions.
• Reduced chalkiness through particle engineering.
• Sweetener systems designed for diabetic or calorie-sensitive patients.
• Pediatric formats with smaller administration volumes.

Ready-to-use and unit-dose formats

Ready-to-use packaging is already central to oral contrast convenience. Further differentiation could involve:

• Single-patient bottles.
• Premeasured preparation kits.
• Tamper-evident closures.
• Easy-grip bottles for patients with limited dexterity.
• Smaller-volume concentrated formats.
• Barcoded packaging linked to imaging workflow systems.

These opportunities are primarily packaging and operational innovations. They may support device, design, trademark, or formulation claims rather than broad composition patents.

Supply-chain resilience

Barium sulfate suspensions rely on consistent raw-material quality, including pharmaceutical-grade barium sulfate, polymers, preservatives, flavors, and packaging components. A manufacturer with dual-source qualification and dependable fill-finish capacity could compete on supply continuity.

This is commercially relevant because diagnostic departments often have limited tolerance for contrast-agent shortages. A supplier able to maintain inventory across hospital and outpatient channels may gain share even without a major price advantage.

Excipient substitution

Excipient substitution can reduce cost or address supply risk. The highest-value substitutions would preserve the product's core performance while improving:

• Raw-material availability.
• Preservative robustness.
• Flavor stability.
• Processing efficiency.
• Shelf life.
• Container compatibility.

Substitution also creates regulatory risk. A change in polymer grade, preservative, flavor, or sweetener may affect product quality and require additional comparability and stability work.

How does READI-CAT 2 compare with other oral barium sulfate products?

Attribute	READI-CAT 2	Generic or private-label oral barium sulfate
Active ingredient	Barium sulfate	Barium sulfate
Primary differentiation	Brand recognition, formulation performance and supply	Price, contract terms and potential packaging variation
Biosimilar risk	None	None
Patent dependence	Likely limited relative to therapeutic drugs	Usually focused on product approval and manufacturing
Formulation challenge	Suspension stability and palatability	Matching or improving those attributes
Switching barrier	Institutional protocols and user familiarity	Low to moderate
Main competitive lever	Reliability and workflow fit	Price, availability and differentiated packaging

READI-CAT 2 is more vulnerable to substitution than a drug with a novel mechanism, but it may retain pricing power where physicians and imaging centers value predictable performance and uninterrupted supply.

What is the revenue exposure for READI-CAT 2?

Public company disclosures generally do not isolate READI-CAT 2 revenue from Bracco Diagnostics' broader contrast-media portfolio. A product-specific revenue estimate would therefore be speculative.

Revenue exposure is likely driven by:

• Volume of abdominal and gastrointestinal CT procedures.
• Hospital and outpatient imaging-center contracts.
• Share of ready-to-use oral contrast purchases.
• Product availability during supply disruptions.
• Pricing pressure from generic and private-label suppliers.
• Uptake of alternative oral contrast products.

The principal financial risk is gradual price erosion rather than an abrupt patent cliff. The principal upside is share retention through formulation quality, packaging convenience, institutional contracts, and reliable supply.

How strong is the READI-CAT 2 patent estate?

The patent estate appears commercially weaker than the estate of a recently launched therapeutic drug because:

• Barium sulfate is an old active ingredient.
• The basic use as an oral radiographic contrast agent is established.
• Common excipients have extensive prior art.
• Generic substitution is technically feasible.
• Manufacturing know-how may be more important than publicly visible patent claims.

Patent strength could still be meaningful if the owner has narrow claims covering a difficult-to-reproduce suspension, a defined particle-size distribution, or an integrated formulation-and-container system. Without evidence of such claims and remaining patent life, the more defensible assessment is that READI-CAT 2's moat is operational rather than patent-driven.

Key Takeaways

• READI-CAT 2 is a 2% w/v oral barium sulfate suspension marketed by Bracco Diagnostics.
• Carboxymethylcellulose sodium and xanthan gum control suspension behavior; sorbitol, sodium saccharin and flavor support palatability.
• The product's main competitive barriers are formulation know-how, manufacturing consistency, packaging, supply reliability and institutional acceptance.
• Biosimilar risk is not relevant because READI-CAT 2 is a chemical diagnostic suspension, not a biologic.
• Generic and private-label entry is technically feasible, with the greatest risks involving suspension performance, taste, microbial control and supply continuity.
• The commercial opportunity is strongest in improved palatability, lower-viscosity delivery, unit-dose packaging, pediatric formats and resilient supply.
• Product-specific revenue cannot be reliably separated from Bracco Diagnostics' broader business using public disclosures.
• The patent estate appears less important than manufacturing and regulatory execution unless narrow formulation or packaging patents remain enforceable.

FAQs

Can READI-CAT 2 be reformulated with different preservatives?

Yes, but preservative substitution can affect antimicrobial protection, taste, pH, stability, packaging compatibility and regulatory comparability. The change would require appropriate quality and stability support.

Is a lower-viscosity barium sulfate product commercially viable?

Yes. Lower viscosity could improve pouring and patient acceptance, but the product must maintain suspension uniformity, redispersion performance and radiographic contrast throughout shelf life.

Can a competitor sell a private-label equivalent of READI-CAT 2?

Potentially. The competitor would need an appropriate FDA approval pathway, compliant manufacturing controls, equivalent product performance and packaging that supports the approved use.

Are flavor patents likely to protect READI-CAT 2?

Flavor-specific claims could exist, but broad protection is difficult because flavor systems and common masking agents have extensive prior art. Narrow claims may protect defined combinations or stability characteristics.

What is the most valuable new product concept in the oral barium sulfate market?

A ready-to-use, unit-dose suspension with improved taste, low sedimentation, reliable redispersion and supply-chain redundancy would have the clearest commercial differentiation.

References

1. U.S. Food and Drug Administration. (n.d.). READI-CAT 2 (barium sulfate) suspension, prescribing information. DailyMed.
2. U.S. Food and Drug Administration. (2023). Approved drug products with therapeutic equivalence evaluations. U.S. Department of Health and Human Services.
3. U.S. Food and Drug Administration. (2024). Abbreviated new drug application submissions: Patent certification and the 30-month stay. U.S. Department of Health and Human Services.